Furthermore, using a CUT&TAG assay in combination with pharmacological inhibition and genetic depletion, we found a novel nonenzymatic dependent function of EZH2 in the transcriptional regulation of CDK4, the cyclin-dependent kinase which play crucial role in breast cancer cell cycle progression, to impair TNBC cell proliferation. Here, EZH2 is linked to breast carcinoma.